United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

galderma (uk) ltd - doxycycline monohydrate - modified-release capsule - 40mg

Ireland - English - HPRA (Health Products Regulatory Authority)

galderma international - doxycycline - modified-release capsule, hard - 40 milligram(s) - doxycycline

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 7 august 1996: ceclor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of ceclor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be perfo

Kenya - English - Pharmacy and Poisons Board

indchemie health specialities pvt. ltd. village : thana, near baddi, tehsil: nalagarh - amoxicillin capsules usp - capsule, hard - each capsule contains amoxicillin trihydrate usp… - beta-lactamantibacterials: second-generation

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 392.3 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - karlor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. karlor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of karlor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - flucloxacillin - capsule, hard - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - clarithromycin citrate - modified-release tablets - 500 milligram

Malta - English - Medicines Authority

mylan products limited - clarithromycin - modified-release tablet - clarithromycin 500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include:
lower respiratory tract infections for example bronchitis and pneumonia.
upper respiratory tract infections for example sinusitis and pharyngitis.
skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - clarithromycin - modified-release tablet - macrolides; clarithromycin